KR20100121207A - 히알루론산 및 l-아르기닌을 함유하는 유착방지제 - Google Patents
히알루론산 및 l-아르기닌을 함유하는 유착방지제 Download PDFInfo
- Publication number
- KR20100121207A KR20100121207A KR1020090040260A KR20090040260A KR20100121207A KR 20100121207 A KR20100121207 A KR 20100121207A KR 1020090040260 A KR1020090040260 A KR 1020090040260A KR 20090040260 A KR20090040260 A KR 20090040260A KR 20100121207 A KR20100121207 A KR 20100121207A
- Authority
- KR
- South Korea
- Prior art keywords
- adhesion
- hyaluronic acid
- arginine
- adhesion agent
- viscosity
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 41
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 41
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 41
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 title claims abstract description 26
- 230000004888 barrier function Effects 0.000 title description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 39
- 229930064664 L-arginine Natural products 0.000 claims abstract description 25
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 25
- 238000001356 surgical procedure Methods 0.000 abstract description 14
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 230000008733 trauma Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000010408 film Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 108010003272 Hyaluronate lyase Proteins 0.000 description 5
- 102000001974 Hyaluronidases Human genes 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 229960002773 hyaluronidase Drugs 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- 206010058667 Oral toxicity Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 231100000418 oral toxicity Toxicity 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-N Agmatine Natural products NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000276425 Xiphophorus maculatus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- QYPPJABKJHAVHS-UHFFFAOYSA-P agmatinium(2+) Chemical compound NC(=[NH2+])NCCCC[NH3+] QYPPJABKJHAVHS-UHFFFAOYSA-P 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- -1 medical devices Substances 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
히알루론산(%) | L-아르기닌(%) | |
비교예 1 | 100 | - |
비교예 2 | - | 100 |
실시예 1 | 75 | 25 |
실시예 2 | 50 | 50 |
실시예 3 | 25 | 75 |
사망률(%) | 이상증상 발생률(%) | 이상증상 내용 | |
비처리군 | 0 | 0 | - |
비교예 1 | 0 | 0 | - |
비교예 2 | 0 | 0 | - |
실시예 1 | 0 | 0 | - |
실시예 2 | 0 | 0 | - |
실시예 3 | 10 | 0 | - |
유착정도 (Adhesion degree) | |
0등급 | 유착발생 없음 |
1등급 | 하나의 얇은 필름형 유착 |
2등급 | 둘 이상의 얇은 필름형 유착 |
3등급 | 점상의 집중화된 두꺼운 유착 |
4등급 | 판상의 집중화된 두꺼운 유착 |
5등급 | 혈관이 형성된 매우 두꺼운 유착 혹은 하나 이상의 판상의 두꺼운 유착 |
유착세기 (Adhesion strength) | |
1 | 필름형이며 매우 약한 힘으로도 떨어지는 유착 |
2 | 중간 정도의 힘이 요구되는 유착 |
3 | 상당한 압력이 걸려야 뗄 수 있는 유착 |
4 | 유착이 매우 강해서 떼기 힘들거나 매우 큰 압력이 요구되는 유착 |
유착정도 | 유착세기 | |
비처리군 | 4.7 | 3.4 |
비교예 1 | 3.5 | 2.5 |
비교예 2 | 4.2 | 3.1 |
실시예 1 | 3.0 | 2.1 |
실시예 2 | 3.4 | 2.3 |
실시예 3 | 3.8 | 3.0 |
히알루로니다아제 투여경과시간(분) |
절대점도(cps) | |||
비교예 1 | 실시예 1 | 실시예 2 | 실시예 3 | |
0 | 1320 | 1450 | 1530 | 950 |
5 | 1238 | 1420 | 1480 | 860 |
10 | 1155 | 1400 | 1400 | 780 |
15 | 1042 | 1370 | 1350 | 700 |
20 | 910 | 1325 | 1290 | 670 |
30 | 800 | 1286 | 1220 | 630 |
45 | 726 | 1253 | 1150 | 610 |
60 | 624 | 1201 | 1000 | 590 |
Claims (7)
- 히알루론산 및 L-아르기닌을 함유하는 유착방지제.
- 제1항에 있어서, 히알루론산 및 L-아르기닌의 비율이 1 : (0.05 ~ 5) 중량비인 것을 특징으로 하는 유착방지제.
- 제1항에 있어서, 히알루론산 및 L-아르기닌의 비율이 75: 25 중량비인 것을 특징으로 하는 유착방지제.
- 제1항에 있어서, 히알루론산의 점도는 500 내지 10,000cps인 것을 특징으로 하는 유착방지제.
- 제1항에 있어서, 히알루론산의 점도는 500 내지 2000cps인 것을 특징으로 하는 유착방지제.
- 제1항에 있어서, 히알루론산의 점도는 1000 내지 2000cps인 것을 특징으로 하는 유착방지제.
- 제1항에 있어서, 히알루론산의 점도는 1000 내지 1500cps인 것을 특징으로 하는 유착방지제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090040260A KR101074467B1 (ko) | 2009-05-08 | 2009-05-08 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090040260A KR101074467B1 (ko) | 2009-05-08 | 2009-05-08 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100121207A true KR20100121207A (ko) | 2010-11-17 |
KR101074467B1 KR101074467B1 (ko) | 2011-10-17 |
Family
ID=43406592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090040260A KR101074467B1 (ko) | 2009-05-08 | 2009-05-08 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101074467B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012057381A1 (ko) * | 2010-10-29 | 2012-05-03 | 주식회사 휴메딕스 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101598329B1 (ko) | 2013-03-20 | 2016-02-29 | 일동제약주식회사 | 히알루론산의 제조방법 및 상기 제조방법으로 제조된 히알루론산을 포함하는 유착방지용 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100785378B1 (ko) * | 2005-09-05 | 2007-12-14 | 주식회사 바이오레인 | 다층구조의 유착방지제 |
-
2009
- 2009-05-08 KR KR1020090040260A patent/KR101074467B1/ko active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012057381A1 (ko) * | 2010-10-29 | 2012-05-03 | 주식회사 휴메딕스 | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 |
Also Published As
Publication number | Publication date |
---|---|
KR101074467B1 (ko) | 2011-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012057381A1 (ko) | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 | |
EP2371371B1 (en) | Composition for preventing adhesion | |
CN106068133B (zh) | 使用生物聚合物的伤口敷料的制备方法、及利用其方法制备的使用生物聚合物的伤口敷料 | |
EP2614828B1 (en) | Low-modification biocompatible high polymer sulfhydryl-modified derivatives, cross-linked material thereof, and uses of said material | |
EP1207828B1 (en) | Hyaluronic acid anti-adhesion barrier | |
KR20230125136A (ko) | 히알루론산-칼슘 및 폴리라이신을 포함하는 창상 피복재및 그 제조 방법 | |
EP1624935B1 (en) | Anti-adhesion composites and methods os use thereof | |
KR20060008906A (ko) | 가교된 다당류 조성물 | |
US20030073663A1 (en) | Bioabsorbable medical devices from oxidized polysaccharides | |
EP3815697B1 (en) | Two-component hemostatic composition and method of manufacturing same | |
KR20170028509A (ko) | 히알루론산염이 코팅된 고 기능성 봉합사의 제조방법 및 이로부터 제조된 고 기능성 봉합사 | |
KR20230126734A (ko) | 의료 기기, 하이드로겔 및 그의 제조 방법과 응용 | |
KR101180286B1 (ko) | 히알루론산 에폭사이드 유도체 하이드로겔을 포함하는 유착방지제 및 이의 제조 방법 | |
US20220273851A1 (en) | Disulfide crosslinked hyaluronic acid gel for postoperative abdominal (pelvic) adhesion prevention and preparation method thereof | |
KR101074467B1 (ko) | 히알루론산 및 l-아르기닌을 함유하는 유착방지제 | |
JP6916353B1 (ja) | 癒着防止用高分子組成物 | |
KR101845885B1 (ko) | 입자형 무세포 진피 기반의 온도감응성 유착방지 조성물의 제조방법 | |
KR20130142272A (ko) | 생체 적합성 고분자를 이용한 이식용 재료의 제조방법 | |
CN114728093A (zh) | 止血及伤口治愈用创伤敷料及其制备方法 | |
EP4368213A1 (en) | Tissue formation agent | |
Konovalova et al. | Biomaterials based on chitosan and its derivatives to prevent adhesion formation | |
Lee et al. | Genotoxicity Study of Carboxymethyl Chitosan-based Hydrogel for Clinical Use | |
Gao et al. | Implantable Polyacrylonitrile-Spermidine Electrospun Nanofibers with Sustainable ROS Scavening Capacity for Osteoarthritis (OA) Therapy | |
KR20150111554A (ko) | 황산콘드로이친을 함유한 유착방지용 조성물과 이의 제조방법 | |
Kim et al. | The Effects of Poloxamer/Sodium Alginate Mixture Barriers on Prevention of Post-Operative Peritoneal Adhesion in Dogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141008 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151008 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161010 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171011 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181010 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191022 Year of fee payment: 9 |